Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
200 shown of 7,026 total abstracts
  1. Abstract 99762026-06-05 · 14:15 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-569 study)
    F. Andre, J. Cortes, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract 94792026-06-05 · 16:30 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-419 study)
    N. Rizvi, E. Winer, S. Antonia, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  3. Abstract TPS80022026-06-01 · 20:15 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-16
    T. Mok, H. Rugo, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 15852026-06-02 · 14:45 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-349
    N. Rizvi, M.C. Garassino, H. Rugo · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  5. Abstract 19692026-06-05 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-449
    J. Cortes, M.C. Garassino, P. Schmid · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 19972026-06-04 · 19:15 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    G. Curigliano, F. Andre, L. Paz-Ares · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 99062026-06-01 · 20:45 CT · S406
    KEYNOTE-849: Keytruda (pembrolizumab) 2L in SCLC
    L. Paz-Ares, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  8. Abstract 43902026-06-04 · 15:30 CT · E450
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-190
    C. Saura, L. Paz-Ares · Royal Marsden Hospital
    Poster SessionGastrointestinal Cancer📄🖼️
  9. Abstract 13472026-06-01 · 21:00 CT · S406
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-560
    J. Brahmer, M. Reck, H. Rugo, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract LBA4009LBA2026-06-03 · 15:45 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-845
    M. Krop, E. Winer, S. Antonia, et al. · University of Chicago
    Late-Breaking Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  11. Abstract 17122026-06-01 · 15:00 CT · Arie Crown Theater
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    S. Peters, C. Saura · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 43192026-06-05 · 18:15 CT · E450
    Long-term follow-up of Trodelvy 3L+ for urothelial carcinoma: ASCENT-421
    R. Herbst, S. Modi, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 64672026-06-02 · 15:45 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in RCC
    C. Robert, G. Curigliano, S. Antonia · University of Chicago
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  14. Abstract 97862026-06-02 · 15:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-312 study)
    J. Cortes, F. Andre, C. Saura · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  15. Abstract 97602026-06-03 · 14:30 CT · Arie Crown Theater
    FLAURA-898: Tagrisso (osimertinib) 2L in NSCLC
    G. Curigliano, F. Andre, M.C. Garassino, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 14382026-06-05 · 20:30 CT · S100A
    MONARCH-789: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    A. Spira, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 12842026-06-05 · 16:00 CT · Hall B1
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    M. Krop, M.C. Garassino, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  18. Abstract 95782026-06-04 · 16:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-645
    C. Robert, S. Peters · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 95922026-06-04 · 18:45 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with NSCLC
    M. Krop, M. Reck, S. Peters, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 97302026-06-01 · 15:15 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    F. Andre, E. Winer · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 96932026-06-04 · 13:00 CT · S406
    Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-881
    T. Mok, C. Robert, F. Andre · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 52352026-06-04 · 16:45 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-650
    T. Mok, R. Herbst, M. Reck · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  23. Abstract 18912026-06-02 · 20:30 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    H. Borghaei, S. Modi, H. Rugo, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 48542026-06-02 · 14:30 CT · S100A
    CheckMate-957: Opdivo (nivolumab) neoadjuvant in HCC
    M.C. Garassino, C. Saura, S. Antonia · Stanford Cancer Institute
    Education SessionGastrointestinal Cancer📄🖼️
  25. Abstract 16842026-06-02 · 19:30 CT · E450
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    F. Andre, J. Brahmer · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 16292026-06-05 · 13:15 CT · S100A
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    T. Mok, E. Winer · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 19302026-06-03 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-410 study)
    S. Modi, T. Mok, H. Rugo, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract 15772026-06-04 · 20:30 CT · E450
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-252
    A. Spira, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract e120282026-06-03 · 14:00 CT · S406
    DESTINY-Breast-179: Enhertu (trastuzumab deruxtecan) adjuvant in gastric
    S. Antonia, E. Winer, M. Krop, et al. · MD Anderson Cancer Center
    Publication OnlyGastrointestinal Cancer📄🖼️
  30. Abstract 99392026-06-04 · 20:00 CT · E450
    Long-term follow-up of Tecentriq 3L+ for NSCLC: IMpower-860
    P. Schmid, H. Rugo, S. Tolaney · Cleveland Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 92682026-06-02 · 20:30 CT · E450
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-605
    N. Rizvi, S. Peters, S. Antonia · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  32. Abstract 68602026-06-05 · 15:45 CT · Arie Crown Theater
    CheckMate-13: Opdivo (nivolumab) 2L in RCC
    A. Spira, G. Curigliano, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract LBA4032LBA2026-06-02 · 20:30 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-64
    M.C. Garassino, S. Tolaney, E. Winer · Dana-Farber Cancer Institute
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  34. Abstract 17102026-06-05 · 14:00 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-601
    R. Herbst, M.C. Garassino, S. Modi · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 96312026-06-04 · 14:15 CT · S100A
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-330
    P. Schmid, A. Spira · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 48422026-06-04 · 18:30 CT · Arie Crown Theater
    EV-446: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    J. Cortes, J. Brahmer · Mayo Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  37. Abstract 43212026-06-01 · 13:30 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    A. Spira, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  38. Abstract 44062026-06-05 · 18:00 CT · E450
    Long-term follow-up of Opdivo 3L+ for HCC: CheckMate-238
    P. Schmid, N. Rizvi, H. Borghaei · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  39. Abstract 53732026-06-02 · 15:00 CT · S406
    Quality of life outcomes with Lynparza in patients with prostate
    G. Curigliano, M. Krop, M.C. Garassino, et al. · Massachusetts General Hospital
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  40. Abstract 14382026-06-02 · 13:45 CT · Arie Crown Theater
    PALOMA-382: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    P. Schmid, M. Reck · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract 93432026-06-02 · 20:15 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with NSCLC
    S. Tolaney, A. Spira, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  42. Abstract 15472026-06-05 · 21:00 CT · Arie Crown Theater
    OlympiA-637: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    T. Mok, S. Tolaney, A. Spira · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 17512026-06-03 · 20:45 CT · S406
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-187
    S. Antonia, M. Reck · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  44. Abstract 43552026-06-04 · 14:45 CT · Arie Crown Theater
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    C. Saura, J. Cortes, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  45. Abstract 91082026-06-02 · 15:15 CT · S406
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-87
    S. Modi, M.C. Garassino, A. Spira · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  46. Abstract 56382026-06-03 · 15:45 CT · E450
    OlympiA-503: Lynparza (olaparib) 1L in prostate
    P. Schmid, C. Robert, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  47. Abstract 49352026-06-04 · 15:30 CT · S406
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-254
    J. Brahmer, E. Winer, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  48. Abstract TPS80472026-06-03 · 14:15 CT · E450
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-945
    M. Reck, J. Brahmer, S. Modi, et al. · Peter MacCallum Cancer Centre
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 15882026-06-05 · 21:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-335 study)
    G. Curigliano, S. Tolaney, J. Cortes · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 10482026-06-05 · 15:45 CT · Hall B1
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    H. Rugo, C. Robert, R. Herbst, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 93912026-06-01 · 21:15 CT · S100A
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-759
    H. Rugo, M.C. Garassino, J. Brahmer, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  52. Abstract 15982026-06-05 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-113
    P. Schmid, E. Winer, N. Rizvi, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 95602026-06-03 · 15:30 CT · S100A
    Quality of life outcomes with Keytruda in patients with SCLC
    R. Herbst, H. Borghaei · MD Anderson Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  54. Abstract 12382026-06-04 · 14:45 CT · S406
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-648
    F. Andre, S. Peters, S. Tolaney · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 12962026-06-04 · 14:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-524
    S. Modi, N. Rizvi · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract LBA4055LBA2026-06-05 · 16:00 CT · E450
    Long-term follow-up of Imfinzi adjuvant for biliary tract: PACIFIC-446
    L. Paz-Ares, G. Curigliano, M. Krop · National Cancer Center Japan
    Late-Breaking Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  57. Abstract LBA4056LBA2026-06-05 · 20:30 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-494 study)
    S. Modi, T. Mok, L. Paz-Ares, et al. · Massachusetts General Hospital
    Late-Breaking Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  58. Abstract 16822026-06-03 · 18:45 CT · E450
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-692
    M. Krop, S. Antonia, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 12792026-06-01 · 16:15 CT · E450
    MONALEESA-292: Kisqali (ribociclib) 1L in HR+ breast cancer
    G. Curigliano, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  60. Abstract 41122026-06-04 · 21:45 CT · E450
    Long-term follow-up of Tecentriq neoadjuvant for HCC: IMpower-465
    C. Robert, J. Cortes, N. Rizvi, et al. · Massachusetts General Hospital
    Poster SessionGastrointestinal Cancer📄🖼️
  61. Abstract 41012026-06-05 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy maintenance for urothelial carcinoma: ASCENT-686
    H. Rugo, T. Mok, N. Rizvi, et al. · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  62. Abstract 12772026-06-03 · 18:15 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Antonia, S. Peters, M.C. Garassino, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 48252026-06-01 · 20:15 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-281 study)
    S. Antonia, J. Cortes, F. Andre · University of Chicago
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  64. Abstract 90662026-06-02 · 13:30 CT · S100A
    IMpower-516: Tecentriq (atezolizumab) 2L in NSCLC
    P. Schmid, J. Brahmer, M. Reck · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  65. Abstract LBA4064LBA2026-06-03 · 13:15 CT · S100A
    Long-term follow-up of Opdivo 3L+ for HCC: CheckMate-402
    J. Brahmer, H. Rugo · Massachusetts General Hospital
    Plenary SessionGastrointestinal Cancer📄🖼️
  66. Abstract e120652026-06-02 · 19:30 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-426 study)
    M.C. Garassino, G. Curigliano, N. Rizvi · University of Chicago
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  67. Abstract TPS80662026-06-04 · 16:45 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-669
    H. Borghaei, C. Robert, P. Schmid, et al. · MD Anderson Cancer Center
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  68. Abstract 12222026-06-03 · 21:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-561
    E. Winer, M. Reck, C. Saura · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 43082026-06-05 · 18:30 CT · S406
    IMpower-666: Tecentriq (atezolizumab) neoadjuvant in HCC
    E. Winer, S. Peters · University of Chicago
    Poster SessionGastrointestinal Cancer📄🖼️
  70. Abstract 19712026-06-04 · 13:15 CT · Arie Crown Theater
    PALOMA-106: Ibrance (palbociclib) maintenance in HR+ breast cancer
    C. Robert, E. Winer · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract LBA4070LBA2026-06-05 · 14:15 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-732 study)
    R. Herbst, S. Modi, S. Antonia, et al. · Vall d'Hebron Institute of Oncology
    Plenary SessionLung Cancer—Small Cell📄🖼️
  72. Abstract 63422026-06-03 · 14:45 CT · E450
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-480 study)
    H. Borghaei, M. Reck, S. Modi · Stanford Cancer Institute
    Poster SessionGynecologic Cancer📄🖼️
  73. Abstract 13472026-06-03 · 15:30 CT · S406
    MONARCH-293: Verzenio (abemaciclib) 2L in HR+ breast cancer
    C. Saura, L. Paz-Ares, S. Peters, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  74. Abstract 93342026-06-05 · 15:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-617 study)
    J. Brahmer, C. Saura, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  75. Abstract 14952026-06-03 · 20:00 CT · E450
    IMpower-158: Tecentriq (atezolizumab) maintenance in TNBC
    L. Paz-Ares, A. Spira, J. Brahmer · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 45462026-06-01 · 16:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-133
    S. Modi, S. Tolaney, H. Borghaei, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  77. Abstract 13472026-06-02 · 16:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-216
    M. Reck, E. Winer, S. Modi, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 15702026-06-01 · 16:15 CT · Hall B1
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    C. Saura, M. Reck · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  79. Abstract 44952026-06-04 · 16:00 CT · S406
    Long-term follow-up of Padcev neoadjuvant for urothelial carcinoma: EV-630
    F. Andre, E. Winer, A. Spira · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  80. Abstract 58892026-06-05 · 15:45 CT · S406
    OlympiA-259: Lynparza (olaparib) 1L in ovarian
    S. Modi, N. Rizvi, M. Krop, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  81. Abstract 17042026-06-04 · 15:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-994 study)
    F. Andre, E. Winer, G. Curigliano, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract TPS80812026-06-02 · 21:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-868
    C. Saura, H. Rugo · Cleveland Clinic
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  83. Abstract 99102026-06-01 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-357 study)
    M.C. Garassino, J. Cortes, S. Peters, et al. · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  84. Abstract 49352026-06-04 · 20:30 CT · Arie Crown Theater
    EV-362: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    M. Krop, R. Herbst · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  85. Abstract 91442026-06-02 · 16:30 CT · E450
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    F. Andre, A. Spira · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  86. Abstract 14302026-06-02 · 14:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-992
    F. Andre, H. Borghaei, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  87. Abstract 42472026-06-03 · 16:00 CT · Hall B1
    EV-850: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    M. Reck, P. Schmid · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  88. Abstract 99952026-06-04 · 16:30 CT · S100A
    FLAURA-888: Tagrisso (osimertinib) 2L in NSCLC
    S. Tolaney, G. Curigliano, J. Cortes · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  89. Abstract 15052026-06-02 · 13:15 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    A. Spira, S. Peters, H. Borghaei, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 46642026-06-01 · 20:45 CT · E450
    Long-term follow-up of Tecentriq 1L for HCC: IMpower-918
    S. Peters, S. Antonia, C. Saura, et al. · Karolinska Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  91. Abstract 14952026-06-02 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-664 study)
    F. Andre, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 10602026-06-03 · 20:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    H. Borghaei, S. Modi, N. Rizvi · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 45642026-06-05 · 19:45 CT · S406
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    M. Krop, P. Schmid, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  94. Abstract 17152026-06-02 · 15:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-682
    A. Spira, S. Tolaney, H. Rugo · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 11832026-06-05 · 16:45 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-363
    M. Reck, S. Tolaney, M.C. Garassino · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 16992026-06-04 · 19:00 CT · S100A
    PALOMA-664: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    H. Rugo, S. Antonia · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  97. Abstract 54922026-06-03 · 13:15 CT · E450
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-120 study)
    C. Saura, E. Winer, R. Herbst · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  98. Abstract 41152026-06-03 · 14:30 CT · E450
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    G. Curigliano, J. Brahmer · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  99. Abstract 12342026-06-03 · 14:00 CT · S100A
    OlympiA-521: Lynparza (olaparib) 2L in HR+ breast cancer
    J. Brahmer, G. Curigliano, N. Rizvi, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract LBA4099LBA2026-06-05 · 15:15 CT · E450
    Long-term follow-up of Tecentriq neoadjuvant for HCC: IMpower-72
    S. Tolaney, N. Rizvi, M. Krop · Chinese University of Hong Kong
    Late-Breaking Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  101. Abstract 49522026-06-04 · 20:45 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-864 study)
    E. Winer, N. Rizvi, T. Mok, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  102. Abstract 45192026-06-04 · 13:30 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-428 study)
    P. Schmid, S. Antonia, C. Saura, et al. · Mayo Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  103. Abstract 40152026-06-02 · 18:00 CT · S100A
    ASCENT-607: Trodelvy (sacituzumab govitecan) maintenance in urothelial carcinoma
    J. Cortes, E. Winer · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  104. Abstract 96252026-06-02 · 15:00 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    T. Mok, S. Modi · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  105. Abstract 19052026-06-04 · 19:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-399 study)
    J. Brahmer, J. Cortes, A. Spira, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 19692026-06-03 · 14:15 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    S. Antonia, P. Schmid, S. Tolaney, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 98982026-06-03 · 21:15 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    J. Brahmer, C. Robert, F. Andre · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  108. Abstract LBA4107LBA2026-06-04 · 18:00 CT · S100A
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-605 study)
    S. Peters, J. Brahmer, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Late-Breaking Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  109. Abstract 90462026-06-05 · 15:45 CT · Hall B1
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-493
    C. Saura, T. Mok, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 17382026-06-02 · 15:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-141
    J. Cortes, E. Winer · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  111. Abstract 92432026-06-01 · 19:15 CT · E450
    DESTINY-Breast-468: Enhertu (trastuzumab deruxtecan) adjuvant in NSCLC
    E. Winer, S. Peters, L. Paz-Ares · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  112. Abstract e121112026-06-05 · 13:30 CT · E450
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-473
    M. Krop, F. Andre · Memorial Sloan Kettering Cancer Center
    Publication OnlyLung Cancer—Non-Small Cell Metastatic📄🖼️
  113. Abstract 61722026-06-03 · 19:30 CT · S406
    Long-term follow-up of Opdivo adjuvant for RCC: CheckMate-204
    H. Rugo, G. Curigliano, N. Rizvi, et al. · University of Chicago
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  114. Abstract 19182026-06-03 · 14:00 CT · S406
    ASCENT-706: Trodelvy (sacituzumab govitecan) 1L in TNBC
    J. Cortes, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  115. Abstract LBA4114LBA2026-06-05 · 13:30 CT · S406
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-205
    S. Antonia, C. Robert, C. Saura · Mayo Clinic
    Late-Breaking Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  116. Abstract 44062026-06-05 · 19:45 CT · S406
    DESTINY-Breast-724: Enhertu (trastuzumab deruxtecan) maintenance in gastric
    F. Andre, P. Schmid, N. Rizvi · University of Chicago
    Poster SessionGastrointestinal Cancer📄🖼️
  117. Abstract 94502026-06-04 · 16:30 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    C. Robert, J. Cortes, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  118. Abstract 61252026-06-05 · 14:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-564 study)
    S. Modi, M. Krop, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  119. Abstract 98552026-06-03 · 15:30 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-717 study)
    M. Reck, S. Modi, R. Herbst · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  120. Abstract LBA4119LBA2026-06-04 · 21:00 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-596
    A. Spira, S. Modi, F. Andre · Vall d'Hebron Institute of Oncology
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  121. Abstract 40502026-06-01 · 19:15 CT · S100A
    Long-term follow-up of Enhertu 3L+ for gastric: DESTINY-Breast-344
    S. Modi, H. Rugo, N. Rizvi, et al. · Institut Gustave Roussy
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  122. Abstract 102092026-06-01 · 21:45 CT · S406
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-734
    G. Curigliano, C. Saura, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  123. Abstract LBA4122LBA2026-06-01 · 13:15 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-337
    J. Cortes, J. Brahmer, G. Curigliano · MD Anderson Cancer Center
    Late-Breaking Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  124. Abstract 12342026-06-01 · 18:00 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-232
    C. Saura, S. Antonia · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 17132026-06-03 · 15:30 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-954
    M.C. Garassino, S. Peters, J. Cortes · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  126. Abstract 43872026-06-03 · 19:15 CT · S406
    EV-489: Padcev (enfortumab vedotin) maintenance in urothelial carcinoma
    C. Saura, J. Brahmer, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  127. Abstract 19112026-06-05 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-203 study)
    H. Borghaei, P. Schmid, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 44382026-06-03 · 20:30 CT · S406
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-358 study)
    J. Brahmer, G. Curigliano, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  129. Abstract 97452026-06-01 · 15:00 CT · Arie Crown Theater
    FLAURA-636: Tagrisso (osimertinib) adjuvant in NSCLC
    C. Robert, E. Winer, C. Saura · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  130. Abstract 17032026-06-01 · 15:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-733
    M. Krop, C. Saura, C. Robert · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  131. Abstract 15142026-06-03 · 15:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-540 study)
    S. Antonia, J. Brahmer, F. Andre, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract TPS81312026-06-05 · 13:00 CT · S100A
    OlympiA-641: Lynparza (olaparib) 1L in HR+ breast cancer
    S. Peters, F. Andre · MD Anderson Cancer Center
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 14292026-06-01 · 14:00 CT · E450
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-638
    J. Cortes, H. Borghaei, M. Reck · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  134. Abstract 42182026-06-01 · 19:45 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in gastric
    P. Schmid, E. Winer, C. Robert, et al. · Massachusetts General Hospital
    Poster SessionGastrointestinal Cancer📄🖼️
  135. Abstract 95872026-06-02 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-740 study)
    T. Mok, S. Peters · Institut Gustave Roussy
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  136. Abstract 11812026-06-02 · 19:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-471 study)
    J. Cortes, M. Reck, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  137. Abstract 95552026-06-03 · 21:00 CT · S100A
    Long-term follow-up of Opdivo 1L for NSCLC: CheckMate-393
    G. Curigliano, M. Reck, S. Peters, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  138. Abstract 11692026-06-01 · 16:00 CT · E450
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-479
    G. Curigliano, R. Herbst, A. Spira, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 49122026-06-05 · 13:30 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    J. Cortes, S. Modi, H. Borghaei, et al. · Cleveland Clinic
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  140. Abstract LBA4139LBA2026-06-02 · 15:45 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in prostate
    L. Paz-Ares, H. Rugo, M. Reck · Peter MacCallum Cancer Centre
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  141. Abstract 98932026-06-02 · 16:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-864
    S. Tolaney, T. Mok, F. Andre, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  142. Abstract e121412026-06-05 · 18:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-734 study)
    S. Tolaney, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  143. Abstract 43782026-06-01 · 19:00 CT · S100A
    Quality of life outcomes with Enhertu in patients with gastric
    H. Borghaei, J. Cortes, S. Tolaney, et al. · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  144. Abstract 95782026-06-01 · 16:30 CT · S406
    KEYNOTE-520: Keytruda (pembrolizumab) 1L in metastatic melanoma
    F. Andre, N. Rizvi, S. Peters, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  145. Abstract 90172026-06-04 · 18:30 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-580
    S. Tolaney, M. Krop, L. Paz-Ares · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  146. Abstract 16622026-06-02 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-964 study)
    T. Mok, F. Andre, N. Rizvi · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  147. Abstract 48592026-06-04 · 13:00 CT · E450
    EV-761: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    T. Mok, E. Winer, M. Reck, et al. · Mayo Clinic
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  148. Abstract 98192026-06-04 · 16:15 CT · S406
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-540
    G. Curigliano, H. Rugo, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  149. Abstract 40012026-06-02 · 16:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-759
    R. Herbst, F. Andre, C. Robert, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  150. Abstract 13492026-06-03 · 18:30 CT · Hall B1
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-725
    S. Peters, F. Andre, J. Cortes, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract LBA4150LBA2026-06-01 · 15:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-472
    L. Paz-Ares, C. Robert, S. Peters · University of Chicago
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  152. Abstract 94272026-06-02 · 19:30 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    J. Brahmer, S. Antonia, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  153. Abstract 99322026-06-02 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-891 study)
    L. Paz-Ares, S. Tolaney, S. Antonia, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  154. Abstract 91522026-06-04 · 20:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-4 study)
    M. Reck, F. Andre · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  155. Abstract 64502026-06-02 · 18:30 CT · E450
    OlympiA-32: Lynparza (olaparib) 3L+ in ovarian
    C. Saura, A. Spira, C. Robert · Peter MacCallum Cancer Centre
    Poster Discussion SessionGynecologic Cancer📄🖼️
  156. Abstract 13012026-06-05 · 16:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-169
    S. Modi, R. Herbst, P. Schmid, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  157. Abstract 93592026-06-01 · 14:00 CT · E450
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-205
    J. Brahmer, S. Tolaney, S. Modi, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Small Cell📄🖼️
  158. Abstract 45942026-06-02 · 21:15 CT · Hall B1
    CheckMate-504: Opdivo (nivolumab) 2L in HCC
    C. Robert, J. Brahmer, T. Mok, et al. · Stanford Cancer Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  159. Abstract 90552026-06-05 · 21:30 CT · S406
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-839
    M. Krop, G. Curigliano, J. Cortes, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  160. Abstract TPS81592026-06-04 · 15:15 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    T. Mok, G. Curigliano, M. Krop, et al. · Massachusetts General Hospital
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 99272026-06-01 · 15:45 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-699
    J. Cortes, H. Borghaei, A. Spira, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  162. Abstract 49812026-06-02 · 15:30 CT · Hall B1
    ASCENT-742: Trodelvy (sacituzumab govitecan) 1L in urothelial carcinoma
    S. Peters, M. Reck, T. Mok, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  163. Abstract 47042026-06-05 · 20:45 CT · Arie Crown Theater
    EV-485: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    J. Cortes, M. Reck · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  164. Abstract 47112026-06-04 · 13:15 CT · Arie Crown Theater
    DESTINY-Breast-936: Enhertu (trastuzumab deruxtecan) 1L in gastric
    L. Paz-Ares, G. Curigliano, H. Rugo · Vall d'Hebron Institute of Oncology
    Poster SessionGastrointestinal Cancer📄🖼️
  165. Abstract 64622026-06-04 · 16:45 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-969
    G. Curigliano, J. Cortes, T. Mok, et al. · Mayo Clinic
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  166. Abstract LBA4165LBA2026-06-03 · 20:30 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    M. Reck, P. Schmid · National Cancer Center Japan
    Late-Breaking Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  167. Abstract 12932026-06-03 · 14:00 CT · S406
    MONARCH-377: Verzenio (abemaciclib) 1L in HR+ breast cancer
    C. Saura, H. Rugo, J. Brahmer, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  168. Abstract 92622026-06-04 · 20:45 CT · S406
    Long-term follow-up of Opdivo adjuvant for NSCLC: CheckMate-529
    T. Mok, N. Rizvi, R. Herbst · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  169. Abstract 103252026-06-02 · 20:45 CT · S406
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-630
    M.C. Garassino, H. Rugo, S. Peters, et al. · Royal Marsden Hospital
    Education SessionMelanoma📄🖼️
  170. Abstract 98882026-06-02 · 18:30 CT · S100A
    FLAURA-637: Tagrisso (osimertinib) 2L in NSCLC
    L. Paz-Ares, A. Spira, N. Rizvi, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  171. Abstract TPS81702026-06-03 · 16:30 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-608 study)
    M.C. Garassino, E. Winer, N. Rizvi, et al. · Stanford Cancer Institute
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 17942026-06-05 · 16:45 CT · E450
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-853
    M. Reck, S. Antonia · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 13802026-06-02 · 15:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-946 study)
    J. Cortes, P. Schmid, A. Spira, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 93342026-06-01 · 18:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-673
    G. Curigliano, S. Peters, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  175. Abstract 69242026-06-02 · 14:45 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-231 study)
    G. Curigliano, N. Rizvi, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  176. Abstract 10512026-06-05 · 21:00 CT · Arie Crown Theater
    OlympiA-667: Lynparza (olaparib) maintenance in HR+ breast cancer
    S. Antonia, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  177. Abstract 65212026-06-04 · 16:15 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with RCC
    M.C. Garassino, T. Mok, S. Antonia, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  178. Abstract 42172026-06-04 · 15:30 CT · Hall B1
    DESTINY-Breast-668: Enhertu (trastuzumab deruxtecan) 2L in gastric
    E. Winer, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  179. Abstract 12002026-06-02 · 18:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-198
    F. Andre, M. Reck, E. Winer, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 12622026-06-04 · 19:30 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-86 study)
    G. Curigliano, S. Antonia, E. Winer, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 15102026-06-03 · 20:45 CT · S406
    MONALEESA-444: Kisqali (ribociclib) 2L in HR+ breast cancer
    N. Rizvi, H. Rugo, A. Spira · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  182. Abstract 42582026-06-04 · 18:30 CT · Arie Crown Theater
    EV-766: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    E. Winer, H. Rugo, J. Cortes, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  183. Abstract LBA4182LBA2026-06-02 · 19:00 CT · E450
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-240
    C. Saura, M.C. Garassino, L. Paz-Ares, et al. · Mayo Clinic
    Plenary SessionGenitourinary Cancer—Prostate📄🖼️
  184. Abstract 40422026-06-02 · 13:15 CT · E450
    EV-489: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    T. Mok, S. Modi, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  185. Abstract 55582026-06-03 · 21:15 CT · S100A
    Quality of life outcomes with Lynparza in patients with ovarian
    G. Curigliano, P. Schmid · Vall d'Hebron Institute of Oncology
    Poster SessionGynecologic Cancer📄🖼️
  186. Abstract 19882026-06-01 · 21:45 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    L. Paz-Ares, H. Rugo · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 15322026-06-01 · 13:00 CT · S406
    OlympiA-889: Lynparza (olaparib) adjuvant in HR+ breast cancer
    G. Curigliano, H. Borghaei · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 47192026-06-02 · 18:30 CT · E450
    Quality of life outcomes with Opdivo in patients with HCC
    H. Borghaei, F. Andre, L. Paz-Ares, et al. · Karolinska Institute
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  189. Abstract 97412026-06-02 · 16:45 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-583
    G. Curigliano, S. Modi, L. Paz-Ares · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  190. Abstract 97182026-06-03 · 21:45 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    C. Saura, M.C. Garassino · Karolinska Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  191. Abstract 68682026-06-01 · 21:15 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-680
    E. Winer, M. Krop · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  192. Abstract 11072026-06-02 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-447
    S. Antonia, M. Krop, J. Cortes, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 16902026-06-01 · 13:30 CT · S406
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-123
    S. Modi, N. Rizvi, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  194. Abstract 58712026-06-05 · 18:00 CT · E450
    Long-term follow-up of Lynparza adjuvant for prostate: OlympiA-434
    H. Borghaei, S. Peters, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  195. Abstract 95382026-06-04 · 20:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-77 study)
    S. Tolaney, J. Brahmer, A. Spira · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  196. Abstract 40412026-06-05 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-5 study)
    L. Paz-Ares, P. Schmid, J. Brahmer · Peter MacCallum Cancer Centre
    Poster SessionGastrointestinal Cancer📄🖼️
  197. Abstract 96512026-06-05 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-960
    T. Mok, N. Rizvi, M.C. Garassino, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  198. Abstract 43542026-06-03 · 21:45 CT · Hall B1
    EV-814: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    F. Andre, M.C. Garassino, R. Herbst · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  199. Abstract 18622026-06-04 · 13:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-375
    L. Paz-Ares, P. Schmid, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 10142026-06-02 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-605 study)
    E. Winer, S. Modi, N. Rizvi, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.